| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | NEUTRAL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.38▲ | 7.34▲ | 7.36▲ | 7.66▼ | 7.02▲ |
| MA10 | 7.35▲ | 7.38▼ | 7.43▼ | 7.40▼ | 7.41▼ |
| MA20 | 7.32▲ | 7.45▼ | 7.60▼ | 7.08▲ | 10.69▼ |
| MA50 | 7.39▼ | 7.69▼ | 7.51▼ | 7.34▲ | 18.90▼ |
| MA100 | 7.44▼ | 7.47▼ | 7.30▲ | 10.97▼ | 25.12▼ |
| MA200 | 7.60▼ | 7.24▲ | 6.93▲ | 17.39▼ | 38.42▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.012▲ | 0.000▼ | -0.042▼ | 0.121▲ | 0.294▲ |
| RSI | 55.069▲ | 42.103▼ | 42.467▼ | 50.736▲ | 31.438▼ |
| STOCH | 79.913 | 36.254 | 23.591 | 71.824 | 25.678 |
| WILL %R | -16.129▲ | -58.824 | -76.271▼ | -47.701 | -88.127▼ |
| CCI | 111.089▲ | -41.176 | -74.031 | 17.307 | -9.240 |
|
Friday, June 13, 2025 04:11 AM
June 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today ...
|
|
Friday, June 13, 2025 04:00 AM
ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In ...
|
|
Friday, June 06, 2025 11:16 AM
Vepdegestrant has been recognized with fast track designation by the FDA and is being co-developed by Arvinas and Pfizer. The recent developments follow the presentation of the VERITAC-2 study at the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/06/25 | 7.40 | 7.5499 | 7.225 | 7.39 | 1,131,045 |
| 12/06/25 | 7.61 | 7.85 | 7.46 | 7.57 | 1,146,038 |
| 11/06/25 | 7.88 | 8.06 | 7.6057 | 7.67 | 2,030,886 |
| 10/06/25 | 7.95 | 8.22 | 7.80 | 7.82 | 2,506,541 |
| 09/06/25 | 7.645 | 7.885 | 7.24 | 7.83 | 3,508,888 |
| 06/06/25 | 7.05 | 7.575 | 7.05 | 7.53 | 2,762,860 |
| 05/06/25 | 6.92 | 7.055 | 6.70 | 6.92 | 1,990,174 |
| 04/06/25 | 7.04 | 7.07 | 6.84 | 6.95 | 1,571,091 |
| 03/06/25 | 7.40 | 7.44 | 6.97 | 7.00 | 2,447,295 |
| 02/06/25 | 6.74 | 7.44 | 6.70 | 7.33 | 4,087,842 |
|
|
||||
|
|
||||
|
|